

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 39/12, C07K 15/00	A1	(11) International Publication Number: WO 92/05799
		(43) International Publication Date: 16 April 1992 (16.04.92)

(21) International Application Number: PCT/US91/06079	(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).
(22) International Filing Date: 26 August 1991 (26.08.91)	
(30) Priority data: 589,722 28 September 1990 (28.09.90) US	
(71) Applicant: HOSPITAL FOR JOINT DISEASES [US/US]; 301 East 17th Street, New York, NY 10003 (US).	Published <i>With international search report.</i>
(72) Inventor: CELADA, Franco ; 41 Bleeker Street, New York, NY 10012 (US).	
(74) Agents: FRANKFORT, Howard, M. et al.; Darby & Darby, 805 Third Avenue, New York, NY 10022 (US).	

(54) Title: METHOD FOR INHIBITING THE INFECTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS**(57) Abstract**

Disclosed herein are methods for inhibiting cell fusion between human T-lymphocytes infected by human immunodeficiency virus (HIV) or free human immunodeficiency virus and uninfected human T-lymphocytes comprising administering inhibitory effective amounts of HIV protein gp120 and CD4-Immunoadhesion and immunogenic compositions for use in the methods.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	CA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in the States of the former Soviet Union.

10

METHOD FOR INHIBITING THE INFECTIVITY
OF HUMAN IMMUNODEFICIENCY VIRUS

Field of the Invention

This application is a continuation-in-part application
15 of co-pending U.S. Patent Application Serial No. 287,270 filed
December 20, 1988.

The government has rights to this invention by virtue
of funding from U.S. Public Service Grant No. R01-AI28194.

One aspect of this invention relates to methods and
20 compositions for influencing the immunogenicity of human im-
munodeficiency virus (HIV) antigens and more specifically to
methods and compositions for raising antibodies that inhibit
the propagation of HIV infection.

Another aspect of this invention relates to antibodies
25 that have the ability to inhibit such propagation.

Background of the Invention

Acquired Immunodeficiency Syndrome (AIDS) is believed
to be caused by a retrovirus called human immunodeficiency
30 virus (HIV), also known as HTLV III or LAV. This syndrome is
considered responsible for a variety of immunologic abnor-
malities including but not limited to the depletion and/or
selective infection by this virus of helper/inducer (T4)
lymphocytes, which results in impairment of the helper/inducer
35 T cell function in affected individuals and in eventual
inhibition of normal immune response in such individuals.

The viral envelope (HIV env) includes a population of
glycoproteins (called gp 160) anchored in the viral cell

membrane bilayer via their C-terminal region. Each glycoprotein contains two segments: the N-terminal segment, called gp120, which protrudes from the membrane into the surrounding medium; and the C-terminal segment, gp 41, which spans the membrane.

It has been reported that HIV infects CD4⁺ T lymphocytes by a sequence of events beginning with attachment of gp120 to its cellular receptor CD4, a nonpolymorphic surface glycoprotein described in Madden, P.G. et al, Cell, 42:93-104, 1985; Clark, S., et al, P.N.A.S. (USA), 84:1649, 1987 and Germain, R.N., Cell, 54:441-444, 1988. It is believed that the binding of gp120 to CD4 then triggers anchorage of gp 41 to the lymphocyte membrane, an event in turn followed by cell fusion between the virion and the target lymphocyte; Kowalski, M. et al, Science, 237:1351-1355, 1987; Gallaher, W.R., Cell, 50:327-328, 1987 and Gonzalez-Scarano, F. et al, AIDS Research & Human Retroviruses, 3(3):245-252, 1987.

In addition, HIV infection is propagated by direct lymphocyte-lymphocyte fusion between virus-infected cells (which have been shown to express gp120 and gp 41 on their surface) and uninfected CD4⁺ cells. This fusion takes place even in the absence of free HIV in the surrounding medium. Lifson, J.D. et al, Science, 232:1123-1127, 1986; Sodroski, J. et al, Nature, 322:470-474, 1986; and Lifson, J.D. et al, Nature, 323:725-728, 1986.

The properties and isolation of gp120 from HIV particles and its sequencing from different HIV isolates are well-known and have been extensively described e.g. in the foregoing references. The preparation of gp120 via recombinant DNA techniques has been described in Lasky, L.A. et al, Science, 233:209, 1986 and in published European patent application of Genentech, Inc. published on August 24, 1988, Serial No. 279,688 (based on U.S.S.N. 155,336 filed 02/12/88) naming Berman, P.W.; Gregory, T.J.; Lasky, L.A.; Nakamura, G.R; et al. as inventors, as well as in Landau, N.R., et al., Nature, 334:159-162, 1988; and Lasky, L.A., et al., Cell, 30:975-985, 1987. Finally, isolation of gp120 (whether native or recom-

binant) has been described in Essex, U.S. Patent No. 4,725,669 (2/16/88).

CD4, the cellular receptor of gp120, has been isolated from lymphocytes. Synthetic (soluble) and recombinant CD4 have been described in Smith, D.H. et al, Science, 238:1704-1707, 1987. Other methods as well as properties of CD4 have been described in Jameson, B.A. et al, Science, 240:1335-1339, 1988; Fisher, R.A. et al, Nature, 331:76-78, 1988; Hussey, R.E. et al, Nature, 331:78-81, 1988; Deen, K.C. et al, Nature, 331:82-84, 1988; Traunecker, A. et al., Nature, 331:84-86, 1988; and Lifson, J.D. et al, Science, 241:712-716, 1988.

Two regions of HIV env (gp 160) exhibit the highest immunogenicity that has been observed against this protein:

The first region has been placed between residues 307 and 330 of gp120 and represents an immunodominant epitope since animals immunized with whole gp 160 or gp120 (or with fragments of gp120 containing the epitope) produce high titers of HIV-neutralizing antibodies (i.e., antibodies that inhibit virion-lymphocyte fusion). This immunodominant epitope is situated in a highly variable segment of gp120 that varies from isolate to isolate and, as a result, the antibodies are also isolate-specific. This limits their utility in immunological studies and in therapy against (or prevention of) HIV infection. Also, sera from HIV-infected humans do not contain high titers of these antibodies.

Instead, sera from infected humans contain HIV-neutralizing antibodies (specifically antibodies that inhibit the binding of viral gp120 to lymphocytic CD4) directed to other epitopes of gp120 which have not been precisely identified (though it is thought to be proximal to the CD4-binding site of gp120); Lasky, L.A. et al, Cell, 50:975-985, 1987. The antibodies are group- and not isolate-specific, which indicates that this second epitope is located in a more conserved domain of gp120. However, animals immunized with gp120, gp 160 or various fragments of gp120 have not produced HIV-neutralizing antibodies. Thus, these other epitopes of gp120 appears to be less immunogenic.

Accordingly, one object of this invention is to provide significant amounts of antibodies that neutralize the infectivity of HIV virus (i.e., inhibit its ability to invade T4 lymphocytes).

5 Another object of this invention is to provide antibodies that prevent HIV-induced cell fusion between healthy T4 lymphocytes and lymphocytes infected with HIV.

10 Yet another object of this invention is to use such antibodies to improve the understanding of the pathogenesis of HIV and to inhibit propagation of HIV infection in human T4 lymphocytes.

Still another object is to provide compositions and methods for raising such antibodies.

15 Further objects of this invention include use of such antibodies in research to elucidate the structure and function of HIV components and the mechanism of HIV infectivity and use of such antibodies in the passive or active immunization of humans for prophylactic or therapeutic purposes.

20 These and other objects of the invention will be apparent to persons skilled in the art in light of the present specification, accompanying claims and appended drawings in which:

Brief Description of the Drawings

25 Figure 1 A-C is a series of plots comparing the magnitude and cell fusion-blocking ability of various antibody titers in successive bleedings of animals immunized with CD4, gp120 and a combination of CD4 and gp120.

30 Figure 2 is a series of graphs illustrating the time course of an experiment with three groups of mice respectively injected with CD4 (A,D,G), CD4-gp120 complex (B,E,H) and gp120 (G,H,I). The weekly serum samples were assayed individually for gp120-binding antibodies (A,B,C), CD4-binding antibodies (D,E,F), and syncytia-blocking capacity (G,H,I). The mice 35 immunized with the complex showed a somewhat higher anti-gp120 response than those immunized with gp120 alone (panels B versus C); a markedly lower titer of CD4 binding as compared to those

receiving CD4 alone (panel E versus D); and a significantly higher syncytia-blocking response (panel H versus G).

Figure 3 is a graph showing titration of 11-week serum from 4 mice injected with CD4-gp120 complex for III_B and RF syncytia-blocking capacity. The parallel behavior of individual sera in the two tests suggests that the antibodies are directed at group-specific determinants.

Figure 4 is a graph showing the effect of antibodies on rCD4-phosphatase binding to solid phase rgp120. In panel A the antibody is OKT4A; in panel B, 94; in panel C, OKT4, in panel D, 55. CD4-phosphatase concentrations: closed circles = 10 micrograms/ml; open circles = 3 micrograms/ml. Ordinate: OD₄₀₅/60 min. Abscissa: antibody concentration, from left to right, 0, 0.3, 1, 3, 10 micrograms/ml.

Figure 5 is a graph showing effect of rgp120 on rCD4-phosphatase binding to various antibodies captured on solid phase goat anti-mouse Ig. In panel A the antibody is OKT4A; in panel B, 94; in panel C, OKT4; in panel D, 55. Concentration of rCD4-phosphatase: closed circles = 10 micrograms/ml; open circles - 1 microgram/ml; squares = 0.1 microgram/ml. Ordinate: OD₄₀₅/60 min (A,B) or OD₄₀₅/120 min (C,D). Abscissa: concentration of gp120 (0, 0.4, 4, 40 micrograms/ml).

Figure 6 is a graph showing the effect of rgp120 on phosphatase-labeled antibody binding to solid phase rCD4. In panel A, the antibody is 94; in panel B, 55. Open circles = no rgp120; closed circles = rgp120 at 0.1 microgram/ml; squares = rgp120 at 1.0 microgram/ml. Ordinate: OD₄₀₅/60 min. Abscissa: antibody concentrations (0.1, 1, 3, 10 micrograms/ml).

30 Summary of the Invention

It has now been discovered that antibodies raised pursuant to immunization with a complex of (a) the HIV antigen gp120 and (b) CD4-Immunoadhesin have the ability to inhibit propagation of HIV infection to healthy human T-lymphocytes (by inhibiting lymphocyte-lymphocyte fusion and invasion of lymphocytes by HIV).

Detailed Description of the Invention

As used in this disclosure, each of the following terms shall have the meaning ascribed to it below.

"gp120" shall mean not only gp120 itself but also any other molecule that binds with CD4 in a similar manner and that when so bound has the same conformation. For example, the term will include fragments of gp120 that bind to CD4 as well as analogs and derivatives of gp120 that possess the ability to bind CD4 and to generate antibodies with the cell-fusion blocking ability of the antibodies of the present invention. In addition, this definition of gp120 shall include gp120 from any HIV isolate since methods for sequencing this protein are known and are independent of the particular isolate of HIV from which the native protein is derived.

"CD4" shall mean CD4 and/or fragments, derivatives or analogs containing the gp120-binding site of CD4, such as CD4 isolated from the lymphocytic surface and CD4 or CD4 derivatives (such as CD4-Immunoadhesin and analogs (e.g. soluble CD4) produced by synthetic (including but not limited to recombinant DNA) techniques.

"gp120/CD4 complex" shall mean a bimolecular (i.e., noncovalent) conjugate or complex between gp120 and CD4 (or between gp120 and antiidiotypic antibody bearing a CD4 internal image). A simple mixture of gp120 and CD4 contains this complex because of the high affinity between gp120 and its cellular receptor. It is not necessary that the complex be made of isolated gp120 and CD4. For example, whole lymphocytes having gp120 bound to the CD4 on their surface are envisioned as a possible form of an immunogen encompassing the gp120/CD4 complex of the present invention. The native lymphocytes of an HIV-infected human would not act as such an immunogen in that human because of the ability of autologous CD4⁺ lymphocytes to act as antigen-presenting cells (APC), as reported by Lanzavecchia, A. et al., Nature, 334:530-532, 1988. (Consequently, the gp120/CD4 complex even if it exists on the surface of these human lymphocytes could not act as an immunogen.) However, antibodies of the type of the present invention could be

induced in a human by immunization with the foregoing complex in one or more of its forms contemplated herein.

"Antibodies of the present invention" or "the present antibodies" shall mean (a) polyclonal, group-specific antibodies raised by immunization with the gp120/CD4 complex and capable of inhibiting lymphocyte fusion; and/or (b) monoclonal antibodies raised against this immunogen and possessing the same fusion inhibiting property.

"Neutralization of HIV" shall mean inhibition of the ability of HIV to bind to and invade a susceptible lymphocyte.

"Cell fusion inhibition" shall mean inhibition of the ability of HIV-infected lymphocytes to form syncytia with healthy CD4⁺ lymphocytes (i.e. lymphocytes possessing surface CD4) in the absence of free HIV.

As stated above, although HIV-infected humans do produce antibodies to gp120 that inhibit the binding of HIV to CD4 and hence prevent invasion of CD4⁺ T lymphocytes (i.e., lymphocytes possessing surface CD4) by the virus, the titers of such antibodies are not very high either in absolute terms or by comparison to these individuals' titers of nonneutralizing antibodies.

The majority of sera from seropositive individuals contain some HIV-neutralizing antibodies directed against an epitope located within a more conserved area of gp120, and distinct from the immunodominant epitope. Such antibodies are group-specific and constitute useful investigative tools in the pathogenesis of HIV and in research efforts to produce abatement or prevention of HIV infection. However, even though these human group-specific antibodies neutralized HIV in vitro and inhibited lymphocyte fusion in vitro, they failed to inhibit lymphocyte invasion by free HIV introduced in the serum of primates passively immunized with the human antibodies. This failure has been attributed to the fact that these antibodies are not directed towards an immunodominant epitope and/or to the insufficient affinity of these antibodies for their antigenic determinant compared with the extremely high affinity of gp120 for its lymphocytic receptor CD4 (the

equilibrium constant of the latter is of the order of 10^{-9} M which is significantly higher than the affinity of most antigens for their antibodies). Also, nonprimate mammalian immune systems do not recognize this epitope of gp120 and consequently animals do not produce such antibodies. Therefore, the need still exists for different antibodies that (a) are group-specific, (b) neutralize the virus and inhibit cell fusion and (c) do not compete with the high-affinity binding of gp120 to CD4.

In accordance with the present invention, comparative experiments were conducted in which animals were immunized with (a) CD4, (b) gp120, and (c) a mixture of CD4 and gp120 which is believed to result in a bimolecular (noncovalent) conjugate or complex between CD4 and gp120 because of the high affinity (10^{-9} M) of gp120 for its receptor.

Animals immunized with CD4 alone exhibited a very high titer of anti-CD4 antibodies. However, only a relatively very small portion of these antibodies inhibited the ability of HIV infection to spread among T4 lymphocytes as measured by a cell fusion assay which tests the ability of HIV-infected lymphocytes to fuse with healthy lymphocytes bearing CD4.

In parallel, another group of animals were immunized with gp120 alone. The anti-gp120 immune response was significant (although not nearly as high as the anti-CD4 response) but the anti-gp120 had no HIV-neutralizing ability (as measured by the same assay).

A third group of animals were immunized with a mixture of CD4 and gp120. The immune response showed the presence of anti-CD4 antibodies (although the titer was significantly lower compared to the anti-CD4 elicited by immunization with CD4 alone) and anti-gp120 antibodies (in amounts comparable to those elicited by immunization with gp120 alone). However, the sera showed a very high titer of cell-fusion inhibiting antibodies.

The antibodies of the present invention are not simply anti (CD4), since the cell-fusion inhibiting titer does not correlate with the titer obtained by the immunization with CD4

alone and since anti CD4 do not possess the cell-fusion inhibiting ability of the antibodies of the present invention. For the same reasons, the antibodies of the present invention do not appear to be simply anti gp120. Furthermore, the 5 present antibodies are not the same as previously observed antibodies which inhibit the event of binding between CD4 and gp120 because the titers of the present antibodies do not correlate with the titers of the previously observed binding-inhibiting antibodies. Finally, the antibodies of the present 10 invention are not elicited except in the presence of the gp120/CD4 complex, as will be illustrated below, and therefore constitute novel and distinct entities.

The HIV-neutralizing ability of the antibodies of the present invention has been measured by a cell-fusion assay 15 developed by Skinner, M.A. et al, J. Virol., 62:4195, 1988. This assay exploits the ability of HIV-infected lymphocytes to form syncytia (fused cells) with healthy but HIV-susceptible (CD4⁺) lymphocytes (in the absence of free HIV), a process that starts by the expression (on the surface of infected lymphocytes) of gp120, which then binds to the CD4 of healthy 20 cells. The assay thus compares the ability of HIV-infected lymphocytes to form such syncytia under experimental conditions with the ability of the infected cells to form syncytia under control conditions, i.e. in the absence of a potential fusion-inhibitor.

This assay is a stringent indicator of HIV-infection inhibition ability by a given inhibitor and in particular by an antibody. Another fusion assay is available that measures the 30 ability of free HIV to invade lymphocytes (i.e., the fusion takes place between the virion and the lymphocytes). However, although many antibodies are available that can inhibit lymphocyte infection by free virus, very few antibodies also inhibit lymphocyte-lymphocyte fusion in the absence of free virus. On the other hand, most, if not all, antibodies that 35 inhibit cell fusion also inhibit infection by free virus.

For these reasons, the performance of the present antibodies in the lymphocyte-lymphocyte cell fusion assay

constitutes good evidence of the HIV-inhibiting ability of such lymphocytes.

The antibodies of the present invention may be thus used to inhibit both invasion of lymphocytes by HIV and spread of HIV infection via lymphocyte fusion and hence constitute good candidates for passive immunization (both prophylactic and therapeutic). Such passive immunization may be combined with cytotoxic agents or coadministered with other HIV inhibitors, such as ricin toxin A chain which when linked to recombinant CD4 has been shown to be selectively toxic to infected T-lymphocytes. Till, M.A., et al, Science, 242:1166-1168, 1988.

In addition, immunization of susceptible mammals with a combination of gp120/CD4 is expected to improve the effectiveness of the immune response of these mammals against HIV infection both preventively and therapeutically.

Other uses for the antibodies of the present invention include use in screening tests for the presence of the gp120/CD4 complex; as research tools to identify new epitopes of gp120 and specifically epitopes that are available only by changes in the conformation of gp120 by CD4 binding and/or vice versa. Monoclonal antibodies in accordance with the invention and especially human monoclonal antibodies represent a preferred form of the present invention and can be used for passive immunization in humans.

In addition, many other uses are contemplated as will be apparent to those of ordinary skill in the art.

Amounts used for immunization in mammals can generally vary from about 10 to about 100 micrograms CD4/kg body weight and from about 13 to about 130 micrograms of gp120/kg body weight. The foregoing amounts are based on the assumption that equivalent amounts of CD4 and gp120 will be used, which is preferred but not necessary. It will be appreciated of course by those of ordinary skill in the field that an excess of one or the other constituent of the complex (i.e., an amount in addition to that sufficient to form a complex with the available amount of the other constituent) is not fatal to the operability of the present invention but an equimolar mixture

of CD4 and gp120 is preferred.

Well-known immunization protocols may be used with or without adjuvant. One preferred protocol involved use of the complex in complete Freund's adjuvant as set forth in Example 1 (of course any other well-known immunization adjuvant can be used or adjuvant can be omitted altogether).

A single immunization is sufficient, but immunization may be repeated 4 weeks after the first injection with an additional optional booster 4 weeks after the second injection in incomplete adjuvant (or without adjuvant). In addition, the immunogenic ability of the complex of the present invention can be boosted by use of carriers such as tetanus toxoid, keyhole limpet hemocyanin, vaccinia virus, diphtheria toxoid, etc., as is well known in the art.

Concentrations of the antibodies of the present invention effective in inhibiting lymphocyte-lymphocyte fusion should be at least sufficient to prevent successful carrying out of the sequence of events that lead to either invasion of the lymphocytes by free HIV or lymphocyte-lymphocyte fusion between any available gp120 (whether on the viral envelope or on the surface of an infected lymphocyte) and CD4⁺ lymphocytes. The upper limit of the effective concentration is irrelevant in vitro. In vivo, the upper limit of the effective antibody concentration may be limited by factors outside the binding mechanism, such as on immune response of the host against the antibodies.

The antibodies of the present invention (whether monoclonal or polyclonal) may be purified by well-known techniques for purification of immunoglobulins, including but not limited to use of precipitation techniques (such as ammonium sulfate precipitation) and/or immunoaffinity chromatography methods (with an antigen as the adsorbent) wherein the desired antibody is preferentially bound to the column or excluded in the eluant; protein A sepharose chromatography; Affigel-blue chromatography; high performance liquid chromatography and combinations of these techniques.

Monoclonal antibodies to the complex of the present

invention may be raised according to well-known techniques, such as those described in Kohler and Milstein, Nature, 256:495, 1975 and in Goding, infra.

In addition, it is believed that human monoclonal antibodies may be raised from immortalized human lymphocytes sensitized against the complex of the present invention in vitro (as described in Reading, C.L., 1982, J. Immunol. Meth., 53:261; Hoffman, M.K. et al in Engleman, E.G. et al (Eds) Human Hybridomas and Monoclonal Antibodies, Plenum Press, New York, 1985, p. 466; Borrebaeck, C.A.K., Trends in Biotechnology, 4:147, 1986) or in vivo (by immunizing humans with the complex as described herein and selecting B-cells with the appropriate specificity). Human C3D⁺ peripheral blood mononuclear lymphocytes can be exposed to Epstein-Barr virus for immortalization. Epstein-Barr virus (EBV) can be obtained from the filtered supernatant of the marmoset cell line B95-8 (Miller, G., and Lipman, M., 1973, PNAS (USA) 70:190) available from the ATCC under Accession No. CRL-1612. Infected lymphocytes are then washed and cultured in RPMI-1640 medium in the presence of fetal bovine serum, glutamine, penicillin and streptomycin in 96-well plates at 10⁴ cells per well. After screening for antibody production, positive cultures can be expanded and cultured further. Cultures with supernatants showing specific reactivity to the complex of the present invention can be subcultured on feeder layers of GK5 human lymphoblastoid cells (derived from GM1500 as described in Kearny, J., N. Engl. J. Med., 309:217, 1983) irradiated with 3000 rads of gamma-radiation. Stable clones can then be subcultured at low densities (10-100 cells) on feeder cells and the subcultures can be expanded. The specificity of the antibodies can be tested by the Skinner et al assay referenced and described herein.

Antiidiotype antibodies can be obtained by immunizing syngenic mice with anti-CD4 monoclonal antibody. A most efficient protocol of immunization is to inject the monoclonal antibodies four times a day at weekly intervals. The total amount injected is 13 doses of 20 micrograms per mouse at each

time. In particular, on day 1, the antibody is injected coupled to KLH (keyhole limpet hemocyanin) in complete Freund's adjuvant; on day 6 the antibody is injected coupled to KLH in incomplete Freund's adjuvant (IFA); on day 13 the antibody is injected coupled to KLH in saline; on day 27 the antibody is injected alone in incomplete Freund's adjuvant. To obtain the monoclonal antibodies, the animals are boosted after 4 to 12 weeks after the last injection by injecting again the monoclonal antibody in incomplete Freund's adjuvant in saline. Spleen fusion with an appropriate myeloma partner is performed 3 days after the boost. Fusion and hybrid growth and selection are then performed in accordance with well-known techniques. The antiidiotypic antibodies bearing CD4 internal image can be identified by testing for binding to gp120 (e.g., by radioimmuno assay, enzyme-linked immunosorbent assay, etc.) and purified using well-known methods including immunoaffinity chromatography using gp120 as the adsorbent.

Again, the complex of the present invention when antiidiotype antibodies ("AA") are used can be formed by mixing gp120 and AA preferably in equimolar amounts and waiting for the two constituents to complex with each other.

The materials used in the present invention may be purified from natural sources or synthesized by well-known (recombinant and other) techniques as described above. In addition, recombinant CD4 and CD4-Immunoadhesin are available from Genentech, Inc. and so is recombinant gp120. If not already obtained in purified form, these materials should preferably be purified prior to use in immunization. Techniques for purification are well-known; see, e.g., U.S. Patent No. 4,725,669 of Essex et al. issued February 16, 1988.

To be effective in inhibiting cell invasion by HIV and cell fusion, the antibodies of the present invention must be present in the vicinity of infected T4 lymphocytes (or HIV-susceptible uninfected T4 lymphocytes) before the gp120 expressed on the surface of infected T4 lymphocytes (or the gp120 on the surface of the virion) binds to its receptor (CD4) on the surface of an uninfected lymphocyte (or on the surface of a

susceptible lymphocyte in the case of infection by free virus). Preferably, the antibodies of the present invention will be present in such vicinity prior to encounter between the gp120-bearing infected lymphocyte (or virus) and the target CD4+ lymphocyte.

5 The invention is further described in the Examples that follow. The purpose of these examples is to illustrate the present invention and not to limit its scope.

10 Example 1: Immunization of Mice and Antibody Titers

Three groups of 4 mice (each weighing 25 g) were immunized as follows:

15 The first group was injected once intraperitoneally (i.p.) with 10 micrograms of CD4 in 0.2 ml of complete Freund's adjuvant.

The second group was injected once i.p. with 12.5 micrograms of gp120 in 0.2 ml of complete Freund's adjuvant.

20 The third group was injected once i.p. with a mixture of 10 micrograms of CD4 and 12.5 micrograms of gp120 (previously incubated together for 30 minutes) in 0.4 ml of complete Freund's adjuvant.

25 The mice were bled weekly over a three-month period and the sera were monitored for CD4- and gp120-binding titers. In addition, the sera were monitored for their ability to block lymphocyte-lymphocyte fusion, according to an assay described in Example 2 below, and for their ability to inhibit binding between CD4 and gp120, according to an assay described in Example 3.

30 CD4 and gp120 titers were determined as follows:

Binding antibodies were assayed by ELISA. Microtiter plates were coated with the appropriate antigen (CD4 or gp120, respectively) at a concentration of 3 micrograms/ml in carbonate buffer 0.1 M, pH 9.6 overnight at 4°C, washed and blocked by incubating them with 1% bovine serum albumin (BSA) 35 in phosphate buffer saline (PBS) for 45 min. at room temperature. A 0.1 ml sample of test serum at various dilutions in PBS were then added and incubated for two hours at room

temperature. The plates were then treated with goat-antimouse antibodies labelled with alkaline phosphatase and finally incubated with PNPP (disodium p-nitrophenyl phosphate) at a concentration of 1 mg/ml in diethanolamine buffer, pH 9.8.

5 Each step was followed by a wash in PBS-Tween 20 buffer. Absorption at OD₄₀₅ was determined 1 hour after incubation with substrate in a Titertek Multiskan MCC 340. The OD readings were converted to micrograms/ml of undiluted serum by interpolation to OD=0.5 and assuming a 1:1 ratio between bound mouse

10 antibody and goat and mouse tracer.

Figure 1A is a plot of the anti-gp120 titer (in micrograms/ml serum) of sera elicited by immunization of mice with gp120 (solid line), CD4 (broken line) and the gp120/CD4 complex (-----) for each weekly bleeding.

15 As evident from Figure 1A, immunization with gp120 alone elicited anti-gp120 antibodies; immunization with CD4 alone elicited no anti-gp120 antibodies; immunization with the complex also elicited anti-gp120 antibodies (i.e. the complex generated formation of antibodies against gp120 alone).

20 Figure 1B is a plot of the anti-CD4 titer (in micrograms/ml serum) of sera elicited by immunization with CD4 alone (broken line), gp120 alone (solid line) and complex (---).

25 In Figure 1B, immunization with CD4 alone elicited a very high anti-CD4 immune response; immunization with the complex elicited a lower but significant anti-CD4 response; and immunization with gp120 alone elicited no anti-CD4 response except after week 7 when a small antiidiotype (anti-(anti gp120)) response was observed.

30

Example 2: Lymphocyte Fusion Assay

The assay to determine the immune serum capacity to block lymphocyte-lymphocyte fusion was described in Skinner, supra. Ten microliters of different dilutions (at least 1:10) of the test serum were distributed in Costar 96 A/2 (half-well) plates.

5x10³ or 10x10³ infected cell partners (from CB/IIIB or

CEM/RF lymphocyte cell line publicly available from National Institute of Allergy and Infectious Disease, Reagent Program respectively infected with HTLV IIIB or HTLV RF isolate available from Dr. Gallo at the National Institute of Health) 5 were added to each well contained in 40 microliters of culture medium. Then, 7×10^4 uninfected CD4 $^{+}$ human lymphocytes (Molt4 available from American Type Culture Collection, Rockville, MD, Accession No. CRL-1582) in 40 microliters of culture medium containing fetal bovine serum were added to the wells and the 10 plates were incubated at 37°C in a 5% CO₂ atmosphere for 20-24 hours. The plates were then read for the occurrence and the number of lymphocyte syncytia in an inverted microscope at a 40-fold enlargement. Giant cells having a size of at least five times the area of normal cells were scored as syncytia 15 produced by cell fusion. In the absence of any antiserum, the syncytia were 50-80/well (control). Fusion-blocking units (FBU) were calculated by converting the percent decrease in syncytia scored relative to the control value and taking into account the serum dilution (1 FBU is defined as the amount of 20 antibody that reduces the number of syncytia to 50% of the control value). The results, in FBU, are plotted in Figure 1C. Again, the solid line represents FBU achieved by immune sera of mice immunized with gp120 alone. In Figure 1C, this value is essentially the same as the control. The broken line 25 represents the fusion-blocking ability of immune sera elicited by immunization with CD4 alone. In Figure 1C, this value is positive but not very high. This is attributable to the fact that anti-CD4 will bind some of the CD4 on the uninfected lymphocyte surfaces and thus prevent the gp120 of the infected 30 lymphocytes from binding to the CD4.

In Figure 1C, the line ----- represents the fusion-blocking ability of immune sera elicited by immunization with gp120/CD4 complex. The FBU of this sera starts at about that of the anti-CD4 sera in week 1 and extends to about 50 times 35 that of the anti-CD4 sera.

Example 3: Monoclonal Antibodies

Monoclonal antibodies will be raised by immunizing mice with complex in accordance with the method of Example 1 (except that two injections can be used spaced 4 weeks apart) optional-
5 ly with a booster using incomplete Freund's adjuvant 4 weeks after the second injection. Three days after the last im-
munization, spleen cells will be obtained, purified and fused
10 with myeloma cells. The spleen of the mouse with the highest fusion-blocking ability will be excised using well-known dissertation techniques. A single-cell suspension will be made up by teasing the spleen as described in Goding, J.W., Monoclonal Antibodies: Principles and Practice, Academic Press, Inc., New York 1983, pp. 50-97 and specifically on p. 64. The spleen cells will be harvested by centrifugation (e.g. 400xg
15 for 5 min.) and washed. Erythrocytes will be removed by ammonium chloride lysis followed by centrifugation. The spleen cells will be counted and approximately 10^8 cells will be used for fusion with commercially available mouse myeloma cells (e.g. SP 20 from American Type Culture Collection under
20 Accession No. CRL-1581). $(2 - 3) \times 10^7$ myeloma cells will be mixed with the spleen cells in serum-free media and centrifuged at 400xg for 5 min. Any remaining medium will be removed by suction. The cell pellet will be suspended in 0.5-1 ml of warm
25 fusion medium containing 10 g of 50% w/v PEG (m.W. 1500) and 10 ml Dulbecco's modified Eagles' Minimum Essential Medium, pH 7.6. The mixture will be stirred, centrifuged and resuspended in fetal bovine serum-containing medium using normal spleen cells as feeders. The cells will then be exposed to HAT selective media and grown in such media in an atmosphere
30 containing 5% CO₂. The cultures will be pulled and fed. Hybrids will be growing and screenable at 10-15 days after incubation begins. Positive clones (i.e. clones secreting fusion-blocking antibody) will be identified and recloned until their secretion of the desirable immunoglobulin is steady and reliable. Monoclonals will thus be obtained. The Skinner et al assay can be used to determine specificity of the desired antibody.

Difficulty in obtaining such monoclonals is not expected because the titers of fusion-blocking antibody are relatively high as demonstrated in previous Examples. If desired, spleen cells secreting anti-CD4 and/or anti-gp120 will 5 be separated first before fusion to maximize the probability of obtaining fusion-blocking monoclonals.

Example 4:

It is known that the HIV infection of CD4⁺ cells can be 10 prevented by antibodies specific for the gp120 binding site on CD4, defined as the V1 domains of CD4 involved in the initial CD4-gp120 binding event, i.e., the region homologous to CDR-2, amino and residues 41-52 (Peterson, A., et al., Cell. 54:65, 1988; Landau, N.R. et al., Nature. 334:159, 1988; Clayton, 15 L.K., Nature. 335:363, 1988; Jameson, B.A. et al., Science. 240:1355, 1988), and in part CDR-3, amino and residues 83-92 (Nara, P.L., et al., Proc. Natl. Acad. Sci. USA. 86:7139, 1989; Sattentau, Q.J., et al., J. Exp. Med. 170:1319, 1989). These 20 antibodies prevent infection by sterically interfering with the binding site.

Poly- and monoclonal antibodies from mice immunized with CD4 complexed to gp120, their binding characteristics and capacity to prevent the formation of HIV-dependent syncytia, are described below. The data presented below demonstrate that 25 there are epitopes on CD4, unrelated to the binding site of gp120, which antibodies can recognize, thus affecting post-virus-binding events that usually lead to infection.

The following materials and methods were used as described below.

30 Recombinant molecules. Soluble recombinant CD4 (rCD4), CD4 immunoadhesin (containing V₁ and V₂ domains of CD4 spliced to the CH2 and CH3 domains of human IgG as described in Byrn, R.A., et al., Nature 344:667, 1990, and recombinant gp120 were obtained from Genentech Inc., South San Francisco, CA.).
35 Animals. Balb-c female mice 10-15 weeks old (Jackson Labs, Bar Harber, ME) were used both for immunization and for production of monoclonal antibodies.

5 Immunizations. Mice were injected intraperitoneally (i.p.) with antigen emulsified in Complete Freund's Adjuvant (CFA, Difco, Detroit, MI). The antigens and doses were a) CD4, 16 micrograms/mouse; b) gp120, 12.5 micrograms/mouse, c) CD4-gp120, 16 micrograms CD4 and 12.5 micrograms gp120, thoroughly mixed and incubated for 20 min, and then emulsified in CFA. The mice were bled prior to immunization and every week after, for 13 weeks. Serum samples were stored at -20°C.

10 Enzymes and substrates. Alkaline phosphatase and glutaraldehyde, used to label antibodies for Enzyme Linked Immunosorbent Assay (ELISA) tests, and substrate paranitrophenyl-phosphate (PNPP) were acquired from Sigma Chemicals (St. Louis, MO).

15 Monoclonal antibodies. The monoclonal antibodies (mAbs) mentioned below are F-91-36, F-91-55 and F-91-94, hereinafter called 36, 55 and 94 respectively. They were derived from a fusion of mouse 91, immunized with CD4-gp120 complex as described above. All these mAbs are IgG₁ subclass.

20 Antibody binding of gp120 and CD4. ELISA tests were performed by coating plates with 10 micrograms/ml gp120 or, respectively, with 3 micrograms/ml rCD4 and incubating them with serial dilutions of the mouse sera starting at 1:100 dilution. Phosphatase-labeled host anti-mouse IgG (obtained from Sigma Chemicals) was used to reveal bound antibodies. Readings were performed in a Titertek automated photometer.

25 Inhibition of gp120 binding to solid phase CD4. After coating the plates with 3-10 micrograms/ml rCD4, 50 micrograms of gp120 (+/- 5 micrograms/ml) were added and incubated for 1 hour, +/- serial two-fold dilution of test antiserum or antibody starting at 100 micrograms/ml concentration. After washing, phosphatase-labeled monoclonal anti-gp120 was applied and incubated 1 hr. The phosphatase activity was then measured by the rate of PNPP hydrolysis. The inhibition caused by the test antibody was expressed in percent decrease from the control gp120 binding.

30 Effect of mAbs on CD4 binding to solid phase gp120. Plates were coated with 3 micrograms/ml gp120. CD4-phosphatase at 10

micrograms/ml and 3 micrograms/ml were incubated separately for one hour with PTH or with the test mAbs at concentrations 0.3, 1, 3 and 10 micrograms/ml. The mixtures were then added to the coated wells and incubated 1 hr. After washing, the amount of bound CD4 was revealed by PNPP.

5 Effect of gp120 on CD4 binding to solid-phase captured mAbs. In separate 96-well plates rgp120 and phosphatase-labeled rCD4 were serially titrated by 10-fold dilution from 80 and 40 micrograms/ml respectively, in different directions on each plate. Equal volumes of each were then combined and incubated 10 2 hr at room temperatures (RT). Simultaneously with the above incubation, the test monoclonals were added to a goat anti-mouse IgG coated plate for 2 hrs at RT, then washed of excess sample. Fifty microliters of the titrated complex was transferred to the captured mAb-GAM plate and incubated it RT for 15 2 hrs, then washed. PNPP substrate was added and color developed.

20 Effect of gp120 on mAbs binding to solid-phase CD4. Plates were coated with 3/micrograms/ml rCD4; 25 microliters of 0.1-1.0 micrograms/ml rgp120 and 25 microliters of scalar concentrations (0.3-10.0 micrograms/ml) of test mAb were added together to the wells and incubated for 2 hr. After washing, the bound mAb was revealed using goat anti-mouse Ig phosphatase-labeled antibody.

25 Cross-inhibition of CD4 binding. Competition mapping of mAb specificities was performed by coating plates with rCD4 and layering alkaline phosphatase-labeled mAbs in the absence and presence of graded concentrations of unlabeled test mAbs whose specific binding sites are known from the literature. OKT4A (binding in V1) and OKT4 (binding in V4) were obtained from Ortho (Diagnostics Systems, Raritan, NJ), anti-Leu3a (binding in V1), L83 (V1-V2), L88 (V1-V2), L120 (V4) were a gift from Dr. David Buck, Becton-Dickinson Laboratories, Mountain View, CA.

30 35 Inhibition of syncytia formation. The cell fusion among CD4+ cell lines acutely infected by the virus requires gp120-CD4 specific binding. The test was performed according to Matthews

et al. (Proc. Natl. Acad. Sci USA 84:5424, 1987). Briefly, GEM cells chronically infected with either HTLV3-III_B or HTLV3-RF were used for each determination. Sera diluted 1:10 were distributed in 96-well A/2 plates (Costar). Five to 10 x 10³ HIV-infected cells were added. 70 x 10³ uninfected Molt 4 cells were admixed and the plates were incubated overnight at 37°C, after which the number of giant cells (>5 times the size of the parental cells) were counted at 40 X magnification. The mouse serum control varied from 50 to 85 giant cells per well.

10 Results

15 1. Polyclonal responses to injection of complexed sCD4-rgp120 in mice.

20 Three groups of four mice were injected once, either with rCD4 alone (Fig. 2, panels A,D,G), with sCD4-rgp120 complex (Fig. 2, panels B,E,H), or with rgp120 alone (Fig. 2, panels C,F,I). The weekly bleedings were titrated over a 3-month period for capacity to bind CD4 (panels D-F) and gp120 (panels A-C), and for capacity to inhibit the formation of syncytia (panels G-I). The overall results were strikingly different among the three groups. Figure 2 displays the individual titers for each parameter and for each group. There were often multiple peaks during the response (panel D) and mice of a single group showed different timings for their peaks (panels D and H). When the timing and magnitude of the binding and neutralizing responses were examined, (a) there was no clear correlation between the titers of gp120 binding and syncytia blocking (R versus H); (b) there was inverse relationship between rCD4 and rCD4-rgp120 immunized groups when rCD4 binding titers and syncytia blocking were compared (D vs. G and E vs. H), (c) there was a small CD4 binding response in the group immunized with rgp120, which could be attributed to anti-idiotypes (panel F).

25 35 2. Polyclonal syncytia-blocking responses by mice receiving CD4-gp120 complexed are not type-specific.

The antisera from mice injected with CD4-gp120 efficiently block syncytia formation caused by such widely different HIV isolates as HTLV3-III_B and HTLV3-RF. Figure 3 shows

individual titrations of the sera from these mice, revealing a similar rank order of the individual responses against the two isolates (93>94>91>92).

5 3. The syncytia-blocking capacity of CD4-gp120 responders is absorbed by CD4 and not by gp120.

To determine whether the high capacity of sera from complex-immunized mice to inhibit syncytia formation was due to anti-CD4 or anti-gp120 antibodies (or to a cooperative action
10 of the two) a series of absorption experiments was performed using soluble and solid phase bound antigens. The samples were subsequently monitored for changes in binding or syncytia-blocking titers. The results are set forth in Table 1 below.

Table 1

Absorption of pooled sera from mice immunized with CD4-gp120, demonstrating that syncytia blocking is associated with anti-CD4.

	<u>Absorbent</u>	<u>CD4 binding O.D.*</u>	<u>gp120 binding O.D.*</u>	<u># syncytia**</u>	
		(%)	(%)	IIIB	RF
5	none	1.216 (100)	.940 (100)	0	3
10	gp120	1.180 (97)	.188 (20)	0	5
15	CD4	.420 (34)	.936 (99)	11	24
	no antiserum	-	-	52	60

*O.D. 405/60 min (color developed by phosphatase hydrolysis of PNPP).

**Syncytia blocking assay as described above.

The results unequivocally attributed the syncytia-blocking capacity to antibodies that recognize the CD4 moiety of the complex rather than anti-gp120, since absorbed anti-gp120 serum showed unaltered syncytia blocking, while the decrease of CD4 binding was accompanied by a significant decrease of syncytia blocking with both isolates tested (Table 1).

30 4. The capacity to inhibit CD4-gp120 binding in vitro correlates with the CD4-binding titer and not with the syncytia-blocking titer.

Since the syncytia-blocking capacity observed was mediated by anti-CD4, the inverse relationship of binding and syncytia-blocking titers in mice receiving CD4 versus CD4-gp120 had to be attributed to a difference in the fine specificity of the anti-CD4 antibodies in the two groups. To further characterize the anti-CD4 antibodies, one test was to compare their relative capacity to inhibit gp120 binding to CD4. The results are set forth in Table 2 below.

Table 2 Difference in fine specificity distribution among polyclonal anti-CD4 antibodies.

	CD4 binding (microgram Ab/ml)	Blocking gp120 binding (U ₅₀ /ml)*	Fusion blocking U ₅₀ /ml)
5	Pool #9 (immunized		
10	CD4-gp120 2.4	80.0	45.0
15	Pool #18 (immunized CD4) 31.0	890.0	7.0

*One blocking U₅₀ is the amount of antibody that reduces to 50% the amount of gp120 bound to CD4-coated wells or, respectively, the number of syncytia in the fusion test. U₅₀/ml was calculated by multiplying 1 U₅₀ unit by the dilution factor for each test.

The results (Table 2) showed high inhibition titers in all mice immunized with CD4 alone and low titers in those immunized with the CD4-gp120 complex, indicating that the blocking of syncytia by the latter appeared to be mediated by a mechanism other than prevention of binding of HIV to its receptor on the cell surface.

30 5. Study of anti sCD4-rp120 responses using monoclonal anti-
bodies.

In order to dissect the polyclonal response of mice immunized with the CD4-gp120 complex, hybridomas were produced from one of these animals, and the resulting antibodies were characterized for capacity to bind CD4, to bind gp120 and to block syncytia formation. The results are set forth in Table 3 below.

Table 3 List of hybridomas obtained from fusion 91, hierarchically ordered according to their supernatant's capacity to bind CD4, and tested for binding gp120 and blocking syncytia formation.

		Clone <u>Designation</u>	Binding CD4 (O.D.)*	Binding gp120 (O.D.)*	# Syncytia at 1/2 dilution**	Syncytia Blocking (%)
10	1	135	1.363	0		
		144	1.208	0		
		148	1.149	.007		
		75	1.059	0		
15	10	215	1.049	0		
		145	.982	0		
		84	.932	0		
		142	.930	.012		
		140	.937	0		
20	20	210	.724	.015		
		185	.672	0		
		143	.599	.009		
		201	.482	0		
		J	.437	.006		
		203	.398	.006		
25	30	15	.385	.010		
		156	.372	.028		
		58	.313	.011		
		224	.308	0		
		146	.255	0		
30	35	55	.182	0	9	80
		165	.157	0		
		36	.153	.041	0	100
		172	.145	.006		
		94	.136	0	0	100
		223	.125	0		
		59	.121	0		
40	45	V	.109	0		
		R	.106	.012		
		48	.106	0		
		35	0	.361		
		40	0	.358		
		M	(.023)	.176		
45	50	68	0	.116		
		116	(.012	0	16	65
		95	0	0	18	60
		32	0	0	18	60
		170	0	0		
[control 46]						
50	55	40	.	.	.	
		
		
		170	0	0		

*O.D. 405/120 min when the supernatant was tested in ELISA on plates coated with CD4 (respectively, gp120). See methods

above.

** Lower than the control are shown.

Table 3 shows an early test of 170 wells with hybridoma clones, ordered according to their CD4 binding capacity. Thirty (i.e., the majority) of the positive clones produced anti-CD; only four produced anti-gp120, and the remainder were negative for both. Three of the anti-CD4 clones (and none of the anti-gp120) exhibited capacity to block syncytia. All borderline positives (i.e. those showing less than 0.100 in the gp120 binding) and those with partial blocking of syncytia (clones 116, 95 and 32) became negative after subcloning. Table 4 below shows a further characterization of the hybridomas when the inhibition of gp120-CD4 binding test was performed.

Table 4
Classification of mAbs from mice immunized with CD4-gp120 complex.

		<u>Binding gp120</u>	<u>Binding CD4</u>	<u>Inhibiting CD4-gp120 Binding*</u>	<u>Group-Specific Syncitia Blocking</u>
	mAbs:				
25	48, 35, 40	+	-	-	-
	68				
30	135, 144, 148	-	+	-	-
	75, 215, 145				
	210, 185, 143				
	94, 36	-	+	+	+
35	55	-	+	-	+

*Cut-off for a positive response was 25% blocking at greater than or equal to a 1:2 dilution.

The anti-CD4 mAbs can be divided into three categories:
 a) those that do not inhibit gp120 binding and do not block syncytia; b) those that do not inhibit gp120 binding and block syncytia; and c) those that inhibit gp120 binding and block syncytia. MAbs 55 and 94 were further studied, as representatives of the latter two categories, respectively. Both were of IgG₁ isotype.

6. Preliminary mapping experiments. The binding site of both mAbs 55 and 94 was localized within the first two domains (V1-V2) of CD4 by binding experiments using the CD4 IgG immunoadhesin (Genentech) which contains the two external domains of CD4 spliced to an immunoglobulin constant region (data not shown). A cross-inhibition experiment using labeled mAbs 94 and 55, was performed. The binding of these mAbs to solid phase CD4 was tested in the presence of a series of anti-CD4 monoclonal antibodies whose epitopes and binding characteristics are shown or partially known from the literature. The results are set forth in Table 5 below.

Table 5

Cross-inhibition of CD4 binding by mAbs 55 and 94.

		Inhibitor mAbs									
		OKT4A	LEU-3A	L83	L88	L92	L120	OKT4	F91-55	F91-94	F91-36
20	mAb 55	-	-	+/-	-	-	-	-	+	-	+
	mAb 94	-	-	-	-	-	-	-	-	+	-

25 *Cut-off point for positivity was 25% or larger decrease in binding when the inhibitor was 6 times more concentrated than the test mAb.

30 The two mAbs were not inhibited by any of the tested antibodies with the exception of L83, which produced a partial but consistent competition (Table 5). These results do not provide a precise mapping of the binding sites of the two mAbs. OKT4A and anti-Leu3a bind in the first and second domains of CD4 and the test showed that neither binding site overlaps with mAbs 55 and 94. L83 recognizes a conformational determinant which is affected by mutations both in region 8-40 (V1) and region 119-188 (V2). These data taken together indicated that the fine specificity of mAbs 55 and 94 are different from most studied antibodies and different from each other.

35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 10100 10105 10110 10115 10120 10125 10130 10135 10140 10145 10150 10155 10160 10165 10170 10175 10180 10185 10190 10195 10200 10205 10210 102

inhibition and possible cooperativity between antibody and gp120, a series of three ELISA tests were performed by which the ternary interaction of CD4, antibody and gp120 was examined by keeping in turn one of the reactants in solid phase, and varying the concentrations of the other two. The results are shown in Figures 4, 5 and 6, which also include curves obtained with reference antibodies OKT4A (which competitively interferes with CD4-gp120 binding) and OKT4A (which does not). In Figure 4 the binding of labeled CD4 to gp120 was slightly enhanced or non-significantly changed in the presence of increasing concentrations of 55, while it was progressively inhibited by 94. In Figure 5 the binding labeled CD4 to solid phase-captured antibody was increased 40% by gp120 in the case of 55 at the highest concentration of CD4, but was unaffected or slightly decreased at lower concentrations of CD4. In the case of 94 there was a progressive decrease of CD4 binding in the presence of increased gp120 concentrations, more evident when CD4 was limiting. In Figure 6, the binding of labeled 55 to solid phase CD4 was moderately enhanced in the presence of 0.1 or 1.0 micrograms/ml gp120 while the binding of 94 was depressed in these conditions.

The conclusions of this series of experiments are that a) mAb 94 behaves always as an inhibitor/competitor of the CD4-gp120 binding, and b) mAb 55 in certain conditions does not interfere with the binding in a way similar to OKT4, while in other conditions it showed a degree of cooperativity with CD4-gp120 binding.

Example 5

The effect of immunizing mice with CD4 immunoadhesin (12.5 micrograms), rgp120 (16.5 micrograms) and the combination of CD4 and rgp120 (12.5 micrograms and 16.5 micrograms, respectively) was studied. Three groups of four mice were immunized as described in Example 4 above, and their antibody response to the immunogens was examined 30 days post-immunization using the techniques described in Example 4 above. The results are set forth in Table 6 below.

I M M U N I Z A T I O N

	16.5 microgram gp120			12.5 microgram Immunoadhesin			16.5 microgram gp120 12.5 microgram Immunoadhesin		
5	51	1	3.6	52	1	0	53	1	1.7
	2		3.0	2	0		2	3.3	
	3		3.6	3	0		3	3.7	
	4		3.2	4	0		4	3.4	
10	55	1	4.3	57	1	0	56	1	4.8
	2		2.8	2	0		2	3.6	
	3		3.8	3	0		3	3.0	
	4		4.3	4	0		4	3.3	
15	<hr/>								
20	51	1	0	52	1	2.0	53	1	2.0
	2		0	2		3.9	2	2.0	
	3		0	3		1.7	3	2.4	
	4		0	4		2.0	4	2.3	
25	55	1	0	57	1	3.3	56	1	3.8
	2		0	2		4.0	2	3.7	
	3		0	3		4.0	3	3.9	
	4		0	4		3.9	4	3.6	
30	<hr/>								
35	51	1	0	52	1	0	53	1	1.0
	2		0	2		0	2	1.9	
	3		0	3		0	3	2.2	
	4		0	4		0	4	1.6	
40	55	1	0	57	1	0	56	1	1.6
	2		0	2		0	2	1.3	
	3		0	3		0	3	0	
	4		0	4		0	4	1.0	
45	<hr/>								

As can be seen in the date set forth in Table 6 above, mice receiving the complex Immunoadhesin-rgp120 responded to gp120 with antibody titers similar to those receiving only rgp120 while these mice responded to CD4 with antibody titers similar to those receiving Immunoadhesin alone. However, mice which were immunized with Immunoadhesin-rgp120 were the only group of mice which showed significant-titers of syncitia-blocking antibodies.

All cited literature and patents or patent applications are incorporated by reference in their entirety.

Appendix of Materials Sources

5	CD4, CD4-Immunoadhesin	Genentech Inc., South San Francisco, CA
	Freund's Adjuvant	Difco Laboratories, Surrey, England
10	goat antimouse immunoglobulin	Sigma Chemical Co., St. Louis, Missouri
	gp120	Genentech Inc., South San Francisco, CA
15	microtiter plates	Linbro available from Fisher Scientific, Springfield, N.J.
	96A half-well plates	Costar available from Fisher Scientific Springfield, N.J.
20	PNPP	Sigma Chemical Co., St. Louis, Missouri
	Tween	Sigma Chemical Co., St. Louis, Missouri
25	Tittertrek Multiskan Apparatus	Flow Laboratories, McLean, Virginia
	RPMI 1640	GIBCO, Grand Island, N.Y.

WHAT IS CLAIMED IS:

1 1. A method for inhibiting cell fusion between human
2 T-lymphocytes infected by human immunodeficiency virus and
3 uninfected healthy human T-lymphocytes, the method comprising:

4 exposing said healthy lymphocytes prior to their
5 binding to said infected lymphocytes to the presence of an
6 inhibitory effective amount of antibodies that have been raised
7 against a complex, said complex comprising (a) HIV protein
8 gp120 and (b) a member selected from the group consisting of
9 (i) CD4-Immunoadhesin, (ii) cell-free CD4 and (iii) an-
10 tiidiotypic antibody to CD4 bearing a CD4 internal image.

1 2. A method for inhibiting invasion of human T-
2 lymphocytes by human immunodeficiency virus (HIV) the method
3 comprising:

4 prior to or after binding of said virus and said
5 lymphocyte, exposing said virus to the presence of an in-
6 hibitory effective amount of antibodies that have been raised
7 against a complex, said complex comprising (a) HIV protein
8 gp120 and (b) a member selected from the group consisting of
9 (i) CD4-Immunoadhesin, (ii) cell-free CD4 and (iii) an-
10 tiidiotypic antibody to CD4 bearing a CD4 internal image.

1 3. A method for raising antibodies that inhibit cell
2 fusion between uninfected human lymphocytes and at least one of
3 (a) human lymphocytes infected with human immunodeficiency
4 virus (HIV) and (b) HIV virus particles, the method comprising:

5 immunizing a mammal with both HIV protein gp120
6 and a member selected from the group consisting of (i) CD4-
7 Immunoadhesin, (ii) cell-free CD4 and (iii) antiidiotypic
8 antibody to CD4 bearing a CD4 internal image.

9 waiting for said mammals to mount an immune
10 response; and

11 collecting said antibodies.

1 4. The method of claim 3 comprising immunizing said

2 mammal with a mixture of said gp120 and said member.

1 5. The method of claim 3 comprising simultaneously
2 immunizing said mammal with said gp120 and said member.

1 6. The method of claim 3 comprising successively
2 immunizing said mammal with said gp120 and said member.




1 7. An immunogenic composition comprising as an active
2 ingredient an immunogenically effective amount of a complex of
3 gp120 and a member selected from the group consisting of (i)
4 CD4-Immunoadhesin, (ii) cell-free CD4 and (iii) antiidiotypic
5 antibody to CD4 bearing a CD4 internal image.

1 8. The composition of claim 7 further comprising a
2 physiologically acceptable medium.

1 9. The composition of claim 7 further comprising an
2 immunization adjuvant.

1 10. The composition of claim 7 further comprising an
2 immunogenicity-enhancing carrier.

1 / 8

FIG. 1A**FIG. 1B****FIG. 1C**




FIG. 2A

FIG. 2B

FIG. 2C

SUBSTITUTE SHEET




FIG. 2D
FIG. 2E
FIG. 2F

SUBSTITUTE SHEET




FIG. 2I




FIG. 2H




FIG. 2G

SUBSTITUTE SHEET

5 / 8




FIG. 3B





FIG. 3A

SUBSTITUTE SHEET




SUBSTITUTE SHEET

FIG. 4A

FIG. 4B

FIG. 4C

FIG. 4D

**SUBSTITUTE SHEET****FIG. 5A****FIG. 5B****FIG. 5C****FIG. 5D**




FIG. 6B
FIG. 6A

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/06079

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC
 IPC(5): A61K 39/12; C07K 15/00
 USCl.: 424/89; 530/350

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System	Classification Symbols
U.S.	424/89; 530/350

Documentation Searched other than Minimum Documentation
 to the Extent that such Documents are Included in the Fields Searched ⁸

Databases: Dialog (Files 5, 154, 155, 157, 399, 357), USPTO
 Automated Patent System (File USP?AT, 1971-1991).

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	Nature, vol. 337, issued 09 February 1989, Capon, et al., "Designing CD4 Immunoadhesins for AIDS Therapy", pages 525-531, ^{see} entire document.	1-10
Y	Proceedings National Academy of Sciences, vol. 85, issued April 1988, Berger, et al., "A Soluble recombinant polypeptide Comprising the Amino-terminal Half of the Extracellular Region of the CD4 Site for Human Immunodeficiency Virus", pages 2357-2361, see abstract.	1-10
Z	Nature, vol. 331, issued 07 January 1988, Hussey et al., "A Soluble CD4 Protein Selectively Inhibits HIV Replication and Syncytium Formation", pages 73-81, see entire document.	1-10

- * Special categories of cited documents: ¹⁰
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

15 October 1991

Date of Mailing of this International Search Report

16 DEC 1991

International Searching Authority

Signature of Authorized Officer

ISA/US

Lynette F. Smith

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Journal of Virology, vol. 63, no. 9, issued September 1989, Sun et al., "Generation and Characterization of Monoclonal Antibodies to the Putative CD4-Binding Domain of Human Immunodeficiency Virus Type 1 Sp120", pages 3579-3585, see abstract.	1-10